Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 3Recurrence 1Pancreatic Neoplasms 1Oligometastatic Lung Adenocarcinoma 1Neoplasm Metastasis 1NSCLC 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Neoplasms 1EGFR Mutation Positive Non-small Cell Lung Cancer 1Carcinoma 1Breast Neoplasms 1

Interventions

Gefitinib 1Erlotinib Hydrochloride 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × EGFR Mutation Positive Non-small Cell Lung Cancer × Erlotinib Hydrochloride × Clear all
NCT01776684 2013-01-28

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Samsung Medical Center

Phase NA Unknown
200 enrolled
Thoracic

EGFR Mutation Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡